Basic Information
| LncRNA/CircRNA Name | PCAT92 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | qPCR, Western blot, RIP, RNA-seq, other |
| Sample | prostate cancer tissues and cell lines (LNCaP, PC3, 22Rv1, RPWE-1, HEK-293T) |
| Expression Pattern | up-regulated |
| Function Description | We have shown that knockdown of PCAT92 in LNCaP cells reduces cell viability and proliferation and down-regulates ABCC4 transcript/protein expression. The shared region between PCAT92 and ABCC4 has a binding site for an oncogenic transcription factor (ZIC2) which is also upregulated in the majority of datasets studied here. ZIC2 binding to the predicted ABCC4 promoter has been confirmed using pull-down assay. Interestingly, under PCAT92 knockdown condition, there is a reduction in the ZIC2 binding to ABCC4 promoter indicating the potential involvement of PCAT92 in the recruitment of ZIC2. We have identified distinct regions on PCAT92 with potential to bind to ZIC2 non-DNA binding Zinc-finger domain and potential for triplex formation near ABCC4 promoter region, which have been experimentally validated. |
| Pubmed ID | 30197753 |
| Year | 2018 |
| Title | A Novel Molecular Mechanism for a Long Non-Coding RNA PCAT92 Implicated in Prostate Cancer |
External Links
| Links for PCAT92 | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |